• The California Cotton & Climate Coalition (“C4”) was created to build capacity within all stakeholders to grow, source, and develop climate-beneficial, farm-forward textiles and supply chains
• Cotton grown through C4 carries the Climate Beneficial(TM) trademark, which requires a rigorous verification process during the lifecycle of the product with an emphasis on enhancing biological life
• Coyuchi recently reported an upward trajectory of 26 percent year-over-year net sales growth and an overall revenue climb of $33.3 million – promoting investment opportunities for the public through Regulation A+

Coyuchi, the gold standard in sustainable luxury home goods, uses 100% organic cotton to manufacture all of its textiles. The company was built on four foundational pillars: protecting the planet, innovating circular design, living sustainably, and enriching the community. In line with this mission, Coyuchi has joined a coalition of companies working together to evolve California’s cotton-growing industry. The California Cotton & Climate Coalition (“C4”) aims to build capacity within all stakeholders to grow, source, and develop climate-beneficial, farm-forward textiles and supply chains. C4 includes Coyuchi, Mate, Outerknown, Reformation, Trace, Circular Systems, Imperial Yarn, Carhartt, Natural Fiber Welding, Laguna Enviro Fabrics, and opportunities for additional companies to join the coalition. These companies are a vital part of the coalition’s ecosystem, which includes farms and farmers, as well as companies purchasing cotton, the coalition team, technical service providers and scientists, and textile development partners (https://ibn.fm/heYax). Led by Fibershed, the cotton grown through the project carries the Climate Beneficial(TM) trademark. The program was designed to scale the implementation of carbon farming practices within the working landscape of California’s Central Valley, benefiting growers, rural communities, the environment, and textile brands working to enhance direct relationships with the people who grow food and fiber. Climate Beneficial(TM) requires a careful verification process, with soil and water infiltration testing, annual monitoring, and continuous trialing of growth methods, to achieve its goals. The program’s focus is to enhance the biological life within irrigated cropland soils, improve soil structure, soil-water holding capacity, natural fertility, and carbon drawdown. This will help increase resilience to drought, counter erosion, and benefit the climate. Coyuchi has seen a very positive trajectory, coming off a 26 percent year-over-year net sales growth in 2021 with an overall revenue climb of $33.3 million. The company recently opened up to outside investors through a Regulation A+ offering (manhattanstreetcapital.com/coyuch) and has exceeded the $1 million mark in funding through its campaign. Previously, Coyuchi itself attracted $20 million in private investor funding from several venture capitalists, including Saffron Hill Ventures. With a focus on stability, Coyuchi’s CEO, Eileen Mockus, believes that the company is well positioned, particularly due to the demand from millennial customers seeking sustainable product options. “We’ve been working on this for years, and we don’t see any indication that customers will be pulling back from this. It’s here to stay,” Mockus said (https://ibn.fm/mLjxx). Regarding C4, Mockus also underlined that no singular brand, farm, retailer, or researcher, has the power or influence to mobilize the change necessary to balance our climate. “Sustainability, especially in textiles where there are so many players in the supply chain, is only achievable when everyone gets a seat at the table – and that’s what makes C4 so crucial,” she added. Mockus also explained that never before have there been so many voices united toward the advancement of regeneration. “Coyuchi is proud to be a founding brand of the Coalition and hopes to influence other businesses to join us on this journey.” For more information, visit the company’s website at www.Coyuchi.com. NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• The Inflation Reduction Act provides consumers with rebates and tax credits towards energy-efficient purchases
• Homeowners will be able to claim as much as $14,000 per household, with the largest credits destined towards the purchase of heat pumps
• GeoSolar Technologies is a key supplier of heat pumps to North American households as part of its revolutionary SmartGreen(TM) Home solution
• Its renewable energy systems enable households to lower both, their carbon footprint as well as their utility bill outlay

Starting January 1st, 2023, going green could be the most cost-effective option for you. The recently passed Inflation Reduction Act provides consumers and homeowners with a host of rebates and tax credits towards energy-efficient purchases, such as appliances, electric vehicles and solar panels. In fact, homeowners could be eligible for rebates amounting to as much as $14,000 for the purchase of energy-efficient items, with the largest credits and rebates available for heat pumps, a high-efficiency system that heats and cools homes in place of conventional furnaces or air conditioners (https://ibn.fm/fRyVL).

“While the upfront cost for a heat pump may be higher, these incentives will definitely help. And over the long term, you might save money depending upon where you live and what fuel and electricity cost in your area,” said Paul Hope from Consumer Reports.

Heat pumps form an integral part of the technology offered by GeoSolar Technologies (“GST”), a Colorado-based climate technology company pioneering an approach into clean energy solutions for households. GeoSolar Technologies have sought to build upon the growing move towards renewable energy adoption thorough a multi-pronged approach which looks to electrify homes using green energy sources. From solar panels on roofs, through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, GeoSolar’s proprietary SmartGreen(TM) Home solution has been designed to dramatically increase the energy efficiency of a conventional household.

Moreover, the technology voids the need for households to depend on conventional utilities or pay utility bills. In fact, a study carried out by the company found that a traditional utility-powered home would possess a carbon footprint of upwards of 8 tons of CO2/year whilst paying annual utility bills of $2,700; in contrast, a GeoSolar-powered home would result in a negligible carbon footprint whilst disbursing less than $100 per annum in utility bills (https://ibn.fm/bCADL).

The adoption of renewable energy systems, such as household solar panel systems, has been relatively lackluster in recent years despite their longer-term economic benefits – largely due to their elevated upfront costs. A residential solar power system can cost anywhere between $3,500 to $16,000, with the wide range a factor of the system being installed as well as the type of panels being utilized (https://ibn.fm/XpZvw).

A key provision contained within the Inflation Reduction Act includes the long-term extension of the investment tax credit, a subsidy which has been instrumental in launching the US solar industry as we know it today. The bill calls for a 10-year extension of subsidies in the form of tax credits valued at 30% of the cost of the installed equipment, which will then step down to 26% in 2033 and 22% in 2034. Moreover, the tax credit also applies to residential adopters of solar technology; in effect, the 30% credit will retroactively apply to anyone who installed their system dating back to the beginning of 2022.

The act has already started to have a dramatic effect, both on solar energy installations as well as the adoption of green energy home solutions, such as the ones offered by GeoSolar Technologies. Solar accounted for 45% of all new electricity-generating capacity added to the US grid through the third quarter of 2022, more than any other electricity source (https://ibn.fm/Ojm08).

“With long-term incentives for clean energy deployment and manufacturing, the solar and storage industry is ready to create hundreds of thousands of new jobs and get to work building out the next era of American energy leadership. This is a crucial window of opportunity that we cannot miss,” stated Abigail Ross Hopper, president of the Solar Energy Industries Association (https://ibn.fm/gl0QB).

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs
• In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure
• The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators
• At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher average blood plasma levels, respectively, than the figure reported when a higher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-grade CBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://ibn.fm/yJIUi), allows for various efficiencies and decreases in adverse side effects. Known as DehydraTECH(TM), the patented technology can be easily incorporated into the formulation and manufacturing processes of existing or new orally ingestible and topical products, according to the company, provided the products are fat soluble. So far, Lexaria has been able to process various active molecules and drugs, including antiviral drugs, nicotine, cannabidiol (“CBD”), vitamins, phosphodiesterase inhibitors, and more, using its DehydraTECH platform technology (https://ibn.fm/7pkwz). Moreover, the company has, as of December 29, 2022, received a total of 28 patents granted worldwide (https://ibn.fm/uuNFW) for several DehydraTECH-processed applications. But what is even more remarkable is the fact that Lexaria has evidenced, through multiple animal and human studies, that its DehydraTECH platform technology increases bio-absorption by up to 10x, reduces the time of onset from as much as 1-2 hours to just minutes, delivers drugs more effectively into the bloodstream, and masks unwanted tastes. And in what adds to the company’s repository of the proven benefits of DehydraTECH, the company recently completed a randomized, double-blinded, placebo-controlled cross-over study of 66 male and female volunteers, its most comprehensive hypertension study yet. Dubbed HYPER-H21-4, the study showed that DehydraTECH-processed CBD had an exceptional safety and tolerability profile. It also evidenced that the formulation resulted in a statistically significant lowering of 24-hour ambulatory blood pressure (“BP”), with the BP lowered for the entire five-week study duration. Furthermore, the BP lowered both for patients not taking any other antihypertensive drugs as well as those currently on antihypertensive medication (https://ibn.fm/Vdk4I). At the time of announcing the results from this study, the company on October 27 stated that “additional study endpoint analyses as described in the complete study protocol are still underway and any relevant material findings will be reported upon in due course….” And in a December 21 news release, Lexaria reported on one of these findings. According to this recent announcement, Lexaria reported that it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH-CBD compared to those of published comparators. In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study (https://ibn.fm/qZ30D). The 2017 trial evidenced an average blood plasma CBD level of 23.0 ng/ml after 22 days (the steady state) of daily dosing at a 5 mg/kg non-Lexaria CBD dose level. Lexaria’s HYPER-H21-4 study, on the other hand, showed that the DehydraTECH technology resulted in a 45.8% higher average blood plasma level (33.3 ng/mL) at DehydraTECH-CBD’s lowest dose level tested of just 3.38 mg/kg. When the dose level was increased to 4.46 mg/kg (the highest in the test), the blood plasma level was 133.4% higher than in the 2017 study at 53.7 ng/mL. On their part, the researchers in the 2017 study evaluated higher CBD dosing at a level of 10 mg/kg, showing a blood plasma level of 62.1 ng/mL. Lexaria’s HYPER-H21-4 study, however, did not see the need to administer a dose as high as 10 mg/kg, with the researchers instead extrapolating the administered dose levels linearly to 10 mg/kg. According to the resulting data trend, a 10 mg/kg dose of DehydraTECH-CBD would result in a plasma level of 149.5 ng/mL, a 141% improvement over the findings contained in the 2017 study. Using the extrapolated data trend, Lexaria also showed that at a dose level of 10 mg/kg, the absorption resulting from the administration of DehydraTECH-CBD would outperform that of the pharmaceutical-grade, synthetic CBD formulation used in the 2019 study. The non-Lexaria synthetic CBD, the 2019 study showed, reached a blood plasma level of 91 ng/mL. By comparison, Lexaria’s linear extrapolation showed that DehydraTECH-CBD absorption would outperform this figure by 64%. “DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the bloodstream, as supported by this pharmaceutical-industry peer comparison,” commented Bunka. “This is extremely important to patients hoping to achieve positive health outcomes while using lower levels of medication with no serious side effects and also important to Lexaria as we pursue FDA registration of DehydraTECH-CBD.” Lexaria hopes to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) this year in anticipation of possible approval to proceed with registered clinical trials evaluating the safety, tolerability, and effectiveness of DehydraTECH-CBD in treating hypertension. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Correlate, through its two subsidiaries, Correlate, and Solar Site Design, is offering a complete suite of proprietary clean energy assessment and fulfillment solutions, viewing such solutions as integral to mitigating the effects of climate change
• The WMO estimated that 2022 would likely be 1.15 degree Celsius warmer than pre-industrial times. It also projected, with a 93% probability, that one of the next five years would be warmer than 2016, which was the warmest year on record at about 1.28 degree Celsius hotter than pre-industrial times
• The spike in temperatures, according to the WMO, will be influenced mainly by countries’ suboptimal efforts to enforce effective climate change action, as has been the case over the past few years
• Correlate continues to drive forward the discussion around clean energy, while also reducing the barrier of entry, allowing real estate owners, businesses, and entire industries, to go green

Correlate Infrastructure Partners (OTCQB: CIPI) is forging a path for big and small companies to utilize energy more efficiently while lowering their overall carbon emissions. Through its two subsidiaries, Correlate and Solar Site Design, the company offers a complete suite of proprietary clean energy assessment and fulfillment solutions, stemming from the understanding that scaling distributed clean energy solutions is key to mitigating the growing effects of climate change. As a tech-enabled development, finance, and fulfillment platform for distributed solutions across North America, Correlate understands the weight of the current climate situation. The company recognizes a looming crisis that, left unattended, could result in irreversible damage to the global climate. Its push for renewable energy, as such, is defined by good intentions. Nevertheless, correlate is optimistic that as time progresses, the uptake of its distributed energy solutions will increase, thus contributing to greener buildings and an overall reduction in their carbon footprint. The World Meteorological Organization (“WMO”) estimated that 2022 was likely to be 1.15 degrees Celsius warmer than pre-industrial times. It further projected, with a 93% probability, that one of the next five years would be warmer than 2016, which was the warmest year on record at about 1.28 degree Celsius hotter than pre-industrial times. According to the WMO, this will largely be influenced by countries’ suboptimal efforts to enforce effective climate change action, which has continued to be the case over the past few years (https://ibn.fm/BaSXu). Correlate It is optimistic that their affordable energy solutions will not only initiate but also sustainably support clean energy adoption, and numbers on the ground are proof of the company’s successful approach. Correlate and Solar Site Design already have an opportunity pipeline of over $100 million in commercial projects with over $20 million in awarded backlog. In addition, the company is confident that even more companies will adopt clean energy alternatives as it progresses into the new year, ultimately presenting an even bigger opportunity for its growth. “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets,” noted Todd Michaels, Correlate’s CEO (https://ibn.fm/4Z0wS). If overall global temperatures are to drop, then renewable energy ought to be adopted by the masses. Correlate is encouraging this adoption and aiding companies to use energy more efficiently with fewer carbon emissions. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months
• Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe
• Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic
• Flora reported a 604 percent YOY increase in revenues for the first half of the year and recently added an increase of 414 percent YOY for the Q3 period

Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is entering the new year with its latest acquisition completed, opening the way for accelerated expansion into Europe’s marketplace. Franchise Global Health Inc. (TSX.V: FGH) announced Dec. 23 that it had completed arrangements for Flora Growth to acquire its issued and outstanding shares, and that the former holders of common shares of Franchise Global Health would be delisted from the TSX Venture Exchange on or about Dec. 28 as the company ends its public reporting obligations (https://ibn.fm/qYmTA). Franchise Global Health Inc. serves 1,200 pharmacies in Germany through its wholly owned subsidiaries ACA Muller and Phatebo, and the company’s acquisition by Flora Growth will provide FGH with important cannabis supply chain security, while Flora will be able to build on the new inroad to the German market and launch farther into Europe from there. “Our full focus is on Germany,” FGH CEO Clifford Starke said during an October webcast about the agreement. “Our strong position is on the distribution front. … Which, if this cannabis market is going to come to life, which we all believe so, … we’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.” Flora has already exported its first high-CBD dried cannabis flower products from Colombia to Switzerland and the Czech Republic. Subsidiary JustCBD, acquired by Flora earlier in the year, registered 79 products with the United Kingdom’s novel foods standards agency as well. Flora operates its Cosechemos cultivation, processing, extraction and isolation facility in Colombia, a country with prime growing conditions that has undergone a renaissance in cannabis cultivation during the past few years as the national government has achieved a framework for legalizing the export of select cannabis products. Flora reported a 604 percent increase YOY in its H1 revenues, and its Q3 financials showed similar momentum as revenue for the three-month period ended Sept. 30 came in at $10.8 million, an increase of 414 percent year over year accompanied by a 703 percent YOY growth in gross profit (https://ibn.fm/xdpYK). In addition to FGH’s early mover advantage in Germany, the company has a footprint in Portugal and Denmark, offering further potential for Flora’s European market ambitions (https://ibn.fm/f9F6K). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research
• The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness
• The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward approval for a Phase 1/2a first-in-human clinical trial
• The report estimates that BiondVax is fully funded for the next 12 months; subsequent to the report’s publication, BiondVax raised an additional $7.3 million net in an underwritten public offering
• Accounting for a ratio change in the company’s ADS and based on a probability-adjusted discounted cash flow (“DCF”) model, Zacks valued the company at $57.00 per share

Calendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. Recently, the company was covered in a recent research report by Zacks Small-Cap Research (https://ibn.fm/DXlTC). The report valued the company at $57.00 per American depositary share (“ADS”) against a share price of $9.87 (as of December 8) and highlighted BiondVax’s recent key milestones, starting with highly statistically significant positive results from a preclinical in-vivo proof-of-concept study of its inhaled anti-COVID-19 nanosized antibodies (“NanoAbs”). Derived from alpacas, a species native to South America, the NanoAbs exhibit superior therapeutic potential for a wide range of diseases, according to BiondVax. Its lead NanoAb candidate, designed to treat COVID-19, has exhibited significant competitive advantages over existing oral therapies and monoclonal antibodies (“mAbs”) (https://ibn.fm/aUlNb). BiondVax intends to further develop NanoAbs as drug candidates for the potential treatment of psoriasis, psoriatic arthritis, and other autoimmune diseases. In the aforementioned study, whose initial results were announced on November 29, BiondVax found that COVID-19-infected Syrian hamsters treated with its inhaled anti-COVID-19 NanoAb candidate had an average weight loss of 3.80% compared to 12.01% for the control group of animals treated with placebo (https://ibn.fm/CKKg6). In addition to the weight, researchers also tracked eight additional parameters, including but not limited to social behaviors and heart rate, which suggested that the inhaled NanoAb therapy resulted in milder and shorter illness. BiondVax anticipates this preclinical proof-of-concept trial will continue in January 2023 and will incorporate additional arms that will test lower therapeutic doses, and a protective prophylactic dose of the inhaled NanoAb, with the resulting data guiding dose selection level for the planned first-in-human trial. The company expects to initiate this Phase 1/2a human clinical trial of the inhaled anti-COVID-19 therapy in the fourth quarter of 2023. Spurring efforts even further, BiondVax announced in the summer that it received scientific advice from the Paul Ehrlich Institute (“PEI”), a part of the German national medicines agency, that addressed preclinical, clinical, and manufacturing development plans for the COVID-19 NanoAb therapy. PEI also indicated support for a combined Phase 1/2a clinical trial among patients with confirmed COVID-19 infection (https://ibn.fm/TEQAT). PEI’s advice is generally considered a first key step towards regulatory approval by the European Medicines Agency (“EMA”), the European parallel of the US Food and Drug Administration (“FDA”). PEI’s advice, the reports notes, would help avoid the need to provide standard-of-care (“SOC”) medicines before the clinical trial participants receive the NanoAb candidate. This would allow BiondVax to assess the safety and efficacy in one small-sized trial instead of two sequential trials that would typically include a large Phase 2 study. The Zacks report also touched on BiondVax’s financial results for the third quarter ending September 30, 2022. Though the company did not report any revenues, it had approximately NIS (New Israel Shekels) 29.4 million (approximately $8.3 million at the exchange rate of 3.543 NIS/US$) in cash and cash equivalents. “With a current burn rate of approximately $1 million per month, we estimate the company has sufficient capital to fund operations for the next 12 months,” David Bautz, Ph.D., the author of the research report, writes. Subsequent to the Zacks report, BiondVax raised an additional $7.3 million net in an underwritten public offering, thereby enabling the company to not only proceed apace with the COVID-19 NanoAb development but also to pursue plans to add a number of new potential NanoAb candidates for indications such as anti-IL-17 NanoAbs for the treatment of psoriasis. Meanwhile, in November, BiondVax effected a ratio change of its ADSs from 1 ADS representing 40 ordinary shares to 1 ADS representing 400 ordinary shares, akin to a reverse stock split of 1 new ADS for every 10 old ADSs. Zacks’ valuation took this ratio change into account. Put together, these factors influenced a valuation of $57.00 per ADS, which is “based on [Zacks’] probability-adjusted DCF [discounted cash flow] model that takes into account potential revenues from the NanoAb platform.” The model is highly dependent on the clinical success of the NanoAb candidates and will be adjusted accordingly based on emerging data. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The CDC estimates that by 2060, over 14 million Americans may be diagnosed with Alzheimer’s, up from the current 6.5 million
• In a surprising study, presented at the 2022 Alzheimer’s Association International Conference, it was noted that this rise could be largely attributed to people’s intake of ultra-processed foods, which was linked to a higher risk of dementia
• Of the 10,000 participants who took part in the study, it was noted that those who ate the most ultra-processed foods had a 28% faster rate of global cognitive decline, and a 25% faster rate of executive function decline compared to those who ate the least amount of overly processed food
• MetAlert is pushing for lifestyle and dietary changes while helping to sensitize people on the risks associated with the consumption of ultra-processed foods
• Even as it continues to design, develop, manufacture, distribute and sell products and services in the GPS/BLE wearable technology space, MetAlert is strongly pushing for healthier dietary and lifestyle alternatives guaranteed to reduce the risk of cognitive decline

MetAlert (OTC: MLRT), a developer of personal protective medical equipment and supplies and a pioneer in wearable GPS, human, and asset tracking systems, has, since its inception, shown a commitment to those afflicted with Alzheimer’s, dementia, and autism (“ADA”). This commitment has gone beyond developing location-sensitive health monitoring devices, particularly with the Centers for Disease Control (“CDC”) estimating that by 2060 over 14 million Americans may be diagnosed with Alzheimer’s, up from the current 6.5 million (https://ibn.fm/XYIKQ). MetAlert is pushing for lifestyle and dietary changes that have proven to lower the risk of cognitive decline. In a recent study presented at the 2022 Alzheimer’s Association International Conference, researchers noted that, of the 10,000 study participants, those who consumed more than 20% of their calories from ultra-processed foods had a higher risk of dementia. It further noted that those who ate the most ultra-processed foods had a 28% faster rate of global cognitive decline and a 25% faster rate of executive function decline than those who ate the least amount of overly processed food (https://ibn.fm/AzAPS). In a separate study published by the Harvard Medical School, it was noted that there is a clear correlation between developing dementia and earlier intake of ultra-processed foods. Researchers cited that switching out an estimated 10% of such foods with an equivalent proportion of unprocessed or minimally processed foods, such as fruits and vegetables, could lower dementia risk by as much as 19%. This study followed the dietary habits of over 72,000 people aged 55 and older over an average of 10 years (https://ibn.fm/VhqyW). “58% of the calories consumed by United States citizens, 56.8% of the calories consumed by British citizens, and 48% of the calories consumed by Canadians come from ultra-processed foods,” noted Dr. Claudia Suemoto, an assistant professor in the division of geriatrics at the University of São Paulo Medical School. With a small order of fries and a regular cheeseburger from McDonald’s containing 530 calories while offering a simple, convenient meal while at it, it is easy to see why ultra-processed foods contribute a huge chunk of people’s daily caloric intake. However, MetAlert is helping to sensitize people on the issue, encouraging them to substitute such foods with better quality alternatives. One way to do so is to prepare food from scratch, a sure way of protecting one’s heart and guarding their brain against dementia and Alzheimer’s disease. This move will benefit not only one’s cognition but also lower one’s risk of obesity, diabetes, cancer, heart and circulation problems, as well as the risk of a shorter lifespan. Moreover, given their high sugar, salt, and fat concentration, these foods promote inflammation throughout the body, leaving one pre-disposed to a growing list of other medical conditions. Even as MetAlert continues to design, develop, manufacture, distribute and sell products and services in the GPS/BLE wearable technology and health data collection and monitoring space, it emphasizes that prevention is better than cure. As such, it pushes people to adopt healthier dietary and lifestyle alternatives that reduce cognitive decline risk. For more information, visit the company’s website at www.MetAlert.com. NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Methane, a potent greenhouse gas, accounts for over 30% of global warming dating back to pre-industrial times
• Despite its connotations as a relatively clean fossil fuel, natural gas is 70-90% made up of methane
• A key source of greenhouse emissions in recent year has been the leakage of methane from natural gas fracking operations
• Renewable Natural Gas presents a carbon neutral alternative to natural gas, with production increasing by over 20% YoY in both, the United States and Canada over the past year
• EverGen Infrastructure Corp. has been at the forefront of the development of North America’s RNG production capacity; by early 2023, the company targets over 230 gigajoules per day of RNG production capacity

Methane, a potent greenhouse gas and major contributor to global warming, has historically borne an association with cow burps and wetlands (https://ibn.fm/qCrGW). Over 80 times more potent than carbon dioxide, methane has been found to account for approximately 30 percent of global warming since pre-industrial times and is currently proliferating faster than at any time since record keeping first began in the 1980s (https://ibn.fm/ks84p). In comparison, natural gas has been hailed as the potential ‘bridge’ fuel towards a greener future, with consumers pointing towards the relatively lower carbon emissions generated through the use of natural gas relative to the likes of crude oil and thermal coal. Nonetheless, and despite its greener connotations and perception as a largely benign fossil fuel, natural gas is composed of 70-90 percent methane (https://ibn.fm/zUc8X), an oft forgotten statistic by natural gas advocates. Over the past decade, nearly two-thirds of all new gas production globally has emerged from the United States and Canada, a result of new natural gas fracking technology. A complex process entailing the injection of highly pressurized water, chemicals, and sand to create and prop open fissures for gas to flow, the United States is currently on track to produce upwards of 100 billion cubic feet of natural gas per day 2022 – much of it, a direct result of fracking technology. To put that figure into perspective, the United States accounted for nearly 24 percent of the globe’s total production of natural gas last year, over a third larger than that of the then second-largest producer, Russia. However, if only one percent of that natural gas production were to escape into the atmosphere during the fracking process, the relative advantages of burning natural gas over ‘dirtier’ fossil fuels is brought into question. As of 2021, the average ‘leakage rate’ of gas amongst U.S. natural gas producers languished at well over 2 percent (https://ibn.fm/9bP4F). A study carried out by NASA’s Jet Propulsion Laboratory in 2015 found that methane levels were unchanged for years, but increased sharply after 2006, growing by 25 million tons a year. Using satellites, NASA were able to conclude that fossil fuel production – in particular, natural gas, was responsible for between 12 and 19 million tons of this additional methane. “Isotopic analysis of gas samples [to track methane leakages] at wellheads across a number of fracking operations could easily prove or disprove [NASA’s] hypothesis,” remarked Anthony Ingraffea, a Professor of Engineering at Cornell University. “If [NASA] is right then we know shale gas operations are making global warming worse, and upending efforts to stay well below 2C.” British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) has been at the forefront of renewable natural gas production in North America, a process which has looked to harness methane as a key input with the eventual goal of manufacturing a ‘cleaner’ alternative to conventional fossil fuels. Unlike regular natural gas, RNG is not obtained from fossil resources; rather, it constitutes a carbon-neutral or even, carbon-negative fuel. Nevertheless, and despite its potential to contribute towards global carbon neutrality goals, RNG production has historically been limited given its relatively high cost and limited availability. However, that paradigm might now be changing. In 2021, RNG production within the United States was equivalent to 660 million gallons gasoline equivalents (“GGE”), an increase of over 20 percent relative to the previous year. While that is a lot of RNG, it remains just a fraction – about 3 percent – of the total natural gas consumption within the U.S. In Canada, the pace of growth has been even faster. The Canadian Biogas Association recently revealed that the production of biogas and renewable natural gas had the potential to halve the nation’s methane emissions by as much as half as of 2030. The movement has gained further impetus with various Canadian provinces introducing mandates to boost RNG use in recent years; in 2019, Quebec mandated that its gas grid would blend a minimum of 1-percent RNG into its feedstock mix, a figure set to rise to as much as 10 percent by 2030. EverGen Infrastructure has sought to capitalize on the move towards increased RNG production, with a publicly stated goal to own over 20 facilities across the country within five years. By early 2023 and following the conclusion of ongoing works at their Alberta-based GrowTEC operation, EverGen anticipates its production capacity to amount to upwards of 230 gigajoules per day of renewable natural gas – the equivalent of powering 100 British Columbia homes for a month. “We are a renewable natural gas energy company. We’re a developer, owner and operator of projects that take organic waste and convert that organic waste into renewable energy in the form of renewable natural gas (‘RNG’),” stated Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure Cop. “If you look back at the benefits of bringing in other sources of energy 20 years ago, there wasn’t one silver bullet for the electrical grid to be as renewable as it is today, with wind, solar and hydro. I think renewable natural gas can hold its own, and at the same time solve a massive waste problem and emissions problem from waste,” he concluded. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• With over 500 million ransomware attacks in 1H2021, corporations have been increasingly looking for ways to safeguard their internal IT systems
• The need for data protection has been further heightened by increased regulatory scrutiny from foreign and domestic governmental agencies
• In the U.S., the recently passed Federal ADPPA privacy law will coincide with California’s Consumer Privacy Act, with the latter set to come into effect on January 1, 2023
• With a broad toolkit focused on data security and management, Data443 have sought to capitalize on the expanding global need for data protection services

Towards the beginning of May 2021, U.S. fuel prices started to unexpectedly spike. The Colonial Pipeline company, operator of a systemically crucial 5,500 mile long pipeline engaged in transporting fuel from the Gulf Coast to the New York metro area was shut down, suspending the flow of over 100 million gallons of fuel every day between Texas and New York (https://ibn.fm/YoGfq). In ensuing days, news would break that DarkSide, an emerging hacking consortium had held the company’s IT systems hostage – freezing its data and threatening to leak sensitive corporate information online. Colonial Pipeline would go on to pay a ransom of $2.3 million or 63.7 bitcoin at the time. Whilst dramatic in nature, the Colonial Pipeline ransomware attack was just one of nearly 500 million ransomware attacks taking place in the first half of 2021, a clear illustration of the need for corporations to engage in more robust cyber security efforts going forward. Focusing in on data security and a privacy-forward methodology, Data443 Risk Mitigation (OTC: ATDS) has emerged as a key player within the cyber security arena, strategically positioned to benefit from increased demand for data protection with its portfolio of software solutions, allowing for a unified approach to data governance and security. In January 2022, Data443 completed the acquisition of certain assets from Centurion Technologies, namely its ransomware protection and device recovery technologies, along with ancillary assets. Not only did the deal provide Data443 with the key technical prowess to comply with recently established requirements from the Cybersecurity & Infrastructure Security Agency (“CISA”), but this also enabled Data443 to build on an established franchise with over 3 million licenses deployed worldwide (https://ibn.fm/EvRvV). Jason Remillard, Data443’s Founder and Chief Executive Officer, commented, “This acquisition represents a major milestone for Data443.  Centurion’s ransomware recovery product has long been a differentiator since we first licensed it in 2021 for our product line. Investments in best-practice security programs, platforms, and frameworks have become a business necessity.” In addition to its ransomware recovery and data protection services, Data443’s extensive product suite has provided the company with the ability to deliver corporate solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. In recent months, data protection has been at the forefront of the global technological agenda, most recently due to the roughly $275 million fine meted out on Facebook parent, Meta by Ireland’s Data Protection Commission; the agency based the fine on Meta’s alleged negligence during a 2019 security hack which would ultimately lead to the personal information of over 533 million Facebook users leaked online. (https://ibn.fm/i9MwX). “With more countries introducing modern privacy laws in the same vein as the General Data Protection Regulation (‘GDPR’), the world has reached a threshold where the European baseline for handling personal information is now the de facto global standard,” explained Nader Henein, research vice president at Gartner. By 2023, 65% of the world’s population is set to have its personal data covered under modern privacy regulations, up from a mere 10% in 2020. The strong momentum underpinning the expansion of global data privacy laws has made it imperative for businesses to incorporate the demands of a rapidly evolving privacy landscape into their business’s data strategy. A failure from a business’s security and risk management department to adapt their personal data handling practices could increasingly expose the business to loss through fines or reputational damages, as highlighted by Meta’s recent travails. That requirement has been further heightened as a result of a spate of new consumer privacy regulations coming into effect. The recently passed Federal American Data Privacy and Protection Act (“ADPPA”), a new privacy law promising Americans many of the same consumer privacy rights as the European Union’s General Data Protection Regulation (“GDPR”) will make the protection of online consumer data privacy a nationwide requirement. Meanwhile and on a state level, the California Consumer Privacy Act (“CCPA”) will become fully operational as of January 1, 2023, with the regulations affording consumers the right to know about the personal information a business collects about them as well as how it is used and shared (https://ibn.fm/5iscH). Data443’s multitude of offerings – an all-encompassing toolset including data archiving, file sharing, access control, sensitive content management and global privacy management, has seen the company pick up an impressive slate of clients in recent months. These include a five-and-a-half-year contract with a “Fortune 500 Fintech Member,” a multi-year contract with a “leading financial services organization in Puerto Rico,” a multi-year contract with a “major US energy provider with over 30,000 employees,” and, only a few weeks ago, a $350,000 contract addition to an existing agreement with “a leading global investment bank headquartered in New York City with over $2 trillion in assets” (https://ibn.fm/VTTMQ). Remillard remarked on the company’s prospects going forward, “We continue to expand the adoption of our product sets in some of the world’s largest organizations, supporting business-critical data in flight and at rest, in the cloud or on-premises. I am confident that Data443 is well positioned to make the most of the substantial market opportunity before us, continuing our mission: To organize the world’s information by identifying and protecting all sensitive data regardless of location, platform, or format,” he concluded. For more information, visit the company’s website at www.Data443.com NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

• Hillcrest Energy began 2022 with proof-of-concept of its innovative traction inverter technology that overcomes shortfalls in today’s tech and improves EV motor efficiency
• The company ended the year with its first 800-volt 250-kilowatt commercial prototype that has attracted the attention of leading EV makers and Tier 1 automotive suppliers
• Hillcrest announced two co-development partners and is now working with them both to integrate the ZVS traction inverter into their specific commercial applications

As the new year arrives, it is a commonplace for companies and investors to reflect upon the last 12 months and hypothesize about where the next year will lead. In the EV space, 2022 will likely be remembered as the start of a steep adoption trajectory as more makes and models hit the roads. In that lane, the year was full of important milestones for Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a developer of high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems. In the words of Hillcrest CEO Don Currie, “the company met or exceeded every milestone we set out to achieve.” Those are confident words from a company that is drawing industry attention for its ZVS inverter technology. Power inverter technology is an unsung hero in Evs that converts high voltage direct current (“DC”) power stored in batteries to the alternating current (“AC”) needed for EV motors. That’s the simple way of putting it. In depth, power inverters convert batteries’ DC electricity into sinusoidal, three-phase, variable frequency AC power to move a car when the accelerator is pushed and subsequently capturing energy released through regenerative braking, converting it into a single DC output to charge the batteries, which helps extend travel range. This complex engineering is being perfected as the industry matures and Hillcrest sits as at the forefront ushering in next generation inverter tech. During 2022, Hillcrest published two technical white papers validating the value of its ZVS inverter technology. The publications highlighted demonstrations of the inverter achieving efficiency exceeding 99.4% at 60 hertz (“Hz”), improvements in motor efficiency of up to 13%, and the ability to reduce the size and weight of DC-link capacitors by as much as 50%. The technology behind the inverter eliminates switching losses and takes advantage of higher switching frequencies at higher voltage than its hard-switched silicon carbide competitors, offering improved motor efficiency, performance, and reliability. These improvements were instrumental in Hillcrest garnering attention of potential customers much earlier in development than anticipated. Before it had completed its first 800-volt 250-kilowatt commercial prototype in December, Hillcrest had already inked two co-development partnerships. Hillcrest isn’t at liberty to disclose everyone that the company is speaking and partnering with, although it has announced two co-development agreements so far. The first is with Hercules Electric Mobility and the second agreement is with a global Tier 1 automotive supplier. Both entities are now collaborating with Hillcrest to integrate the ZVS traction inverter into each partner’s specific commercial application. As it establishes its footprint in the green energy markets, the one-time fossil fuel play has ceased operations at its oil and gas asset, aside from activities required to successfully reclaim the property. Hillcrest is now 100% a clean energy company. To meet its goals, Hillcrest strengthened its leadership team in 2022, hiring firmware engineers with expertise in electric vehicles and grid-tied applications. “We’ve assembled an incredible team with deep understanding and expertise, from technology development to the commercialization and implementation stages,” said Hillcrest CTO Ari Berger in a statement. The company also onboarded David Farrell as Board Chairman and named Michael Moskowitz to the Board and Chairman of the Board’s Executive Committee. “We entered the year with a proof of concept for our core technology, the Hillcrest ZVS inverter technology, and progressed through design, commissioning and finally completion of our first customer-centered product,” added Currie. “Our technical team has delivered at every level and excitement is building around even bigger expectations in 2023.” For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF